G. Zini, Diagnostics and Prognostication of Myelodysplastic Syndromes, Ann Lab Med. nov, vol.37, issue.6, pp.465-74, 2017.

S. H. Swerdlow, E. Campo, N. L. Harris, and E. S. Jaffe, WHO classification of tumours of haematopoietic and lymphoid tissues

P. Weltgesundheitsorganisation, . Sa, H. Stein, J. Thiele, and . Lyon, International Agency for Research on Cancer; 2017. 585 p. (World Health Organization classification of tumours)

A. Maassen, C. Strupp, A. Giagounidis, A. Kuendgen, K. Nachtkamp et al., Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts, Leuk Res. janv, vol.37, issue.1, pp.64-70, 2013.

J. Neukirchen and M. Lauseker, Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study

A. T. Look, Molecular Pathogenesis of MDS, Hematol Am Soc Hematol Educ Program, pp.156-60, 2005.

L. Malcovati and M. Cazzola, The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). ASH Educ Program Book, 12 mai, vol.2015, issue.1, p.307, 2015.

K. Dao, Myelodysplastic syndromes: updates and nuances, Med Clin North Am. mars, vol.101, issue.2, p.50, 2017.

R. Bejar and B. L. Ebert, The genetic basis of myelodysplastic syndromes, Hematol Oncol Clin North Am. avr, vol.24, issue.2, pp.295-315, 2010.

M. Cazzola, D. Porta, M. G. Malcovati, and L. , The genetic basis of myelodysplasia and its clinical relevance, Blood. 12 déc, vol.122, issue.25, pp.4021-4055, 2013.

G. Montalban-bravo and G. Garcia-manero, Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management, Am J Hematol. 1 janv, vol.93, issue.1, pp.129-176, 2018.

P. L. Greenberg, Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment, Leuk Res. 1 déc, vol.22, issue.12, pp.1123-1159, 1998.

D. P. Steensma, R. Bejar, S. Jaiswal, R. C. Lindsley, M. A. Sekeres et al., Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood. 2 juill, vol.126, issue.1, pp.9-16, 2015.

L. Yang, Y. Qian, E. Eksioglu, P. K. Epling-burnette, and S. Wei, The inflammatory microenvironment in MDS, Cell Mol Life Sci. 1 mai, vol.72, issue.10, pp.1959-66, 2015.

E. Grignano, V. Jachiet, P. Fenaux, L. Ades, O. Fain et al., Autoimmune manifestations associated with myelodysplastic syndromes, Ann Hematol. nov, vol.97, issue.11, pp.2015-2038, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01960324

N. Ifrah and M. Maynadié, Société Française d'Hématologie, 2018.

M. J. Rauh, Standardizing dysgranulopoiesis in MDS and AML: refining diagnostics and laying the foundation for novel morphological-genetic correlations, Leuk Res. avr, vol.38, issue.4, pp.428-437, 2014.

T. Glauser and E. Sagatys, Current pathology practices in and barriers to MDS diagnosis

L. Senent, L. Arenillas, E. Luño, J. C. Ruiz, G. Sanz et al., Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes, Haematologica. 1 avr, vol.98, issue.4, pp.568-75, 2013.

S. Parmentier, J. Schetelig, K. Lorenz, M. Kramer, R. Ireland et al., Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors, Haematologica. mai, vol.97, issue.5, pp.723-753, 2012.

U. Germing, C. Strupp, A. Giagounidis, R. Haas, N. Gattermann et al., Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes, Leuk Res. juin, vol.36, issue.6, pp.727-761, 2012.

, Haematologica Atlas of Hematologic Cytology

J. Goasguen, J. M. Bennett, and R. A. , Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areas
URL : https://hal.archives-ouvertes.fr/hal-01880991

D. Sur,

V. Jolly and J. , Traite Technique D'Hermatologie. Morphologie -Histogenese -Histophysiologie -Histopathologie 2 Volumes von, Jolly J

J. E. Goasguen, J. M. Bennett, B. J. Bain, R. Brunning, M. Vallespi et al., Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes, Leuk Res. avr, vol.38, issue.4, pp.447-53, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01147036

S. S. Gustke, G. A. Becker, J. C. Garancis, N. F. Geimer, and A. V. Pisciotta, Chromatin Clumping in Mature Leukocytes: A Hitherto Unrecognized Abnormality, Blood, vol.35, issue.5, pp.637-658, 1970.

U. Mittwoch, Frequency of Drumsticks in Normal Women and in Patients with Chromosomal Abnormalities, Nature, vol.201, issue.4916, pp.317-319, 1964.

J. E. Goasguen, J. M. Bennett, B. J. Bain, R. D. Brunning, M. Vallespí et al., Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: Difficulties in the assessment of dysplasia, Leukemia Research, vol.45, pp.75-81, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01301508

V. Eclache, M. Lafage-pochitaloff, C. Lefebvre, D. Penther, S. Raynaud et al., Cytogenetic place in managing myelodysplastic syndromes: an update by the Groupe francophone de cytogénétique hématologique (GFCH), Annales de biologie clinique, vol.74, issue.5, pp.525-534, 2016.

A. Sebaa, L. Ades, F. Baran-marzack, M. Mozziconacci, D. Penther et al., Incidence of 17p deletions andTP53mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion, Genes, Chromosomes and Cancer, vol.51, issue.12, pp.1086-1092, 2012.

A. E. Wiktor, D. L. Van-dyke, J. M. Hodnefield, J. Eckel-passow, and C. A. Hanson, The significance of isolated Y chromosome loss in bone marrow metaphase cells from males over age 50 years, Leukemia Research, vol.35, issue.10, pp.1297-1300, 2011.

B. Kwok, J. M. Hall, J. S. Witte, Y. Xu, P. Reddy et al., MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance, Blood, vol.126, issue.21, pp.2355-2361, 2015.

A. Nazha, D. P. Seastone, M. Keng, S. Hobson, M. Kalaycio et al., The Revised International Prognostic Scoring System (IPSS-R) is not predictive of survival in patients with secondary myelodysplastic syndromes, Leukemia & Lymphoma, vol.56, issue.12, pp.3437-3439, 2015.

E. Papaemmanuil, M. Gerstung, L. Malcovati, S. Tauro, G. Gundem et al., O-001 Clinical and biological implications of gene mutations in MDS, Leukemia Research, vol.37, issue.22, p.S9, 2013.

R. Bejar, K. E. Stevenson, B. A. Caughey, O. Abdel-wahab, D. P. Steensma et al., Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.30, issue.27, pp.3376-3382, 2012.

A. Nazha, M. Narkhede, T. Radivoyevitch, D. J. Seastone, B. J. Patel et al., Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes, Leukemia, vol.30, issue.11, pp.2214-2220, 2016.

S. S. Patel, M. A. Sekeres, and A. Nazha, Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure, Leukemia & Lymphoma, vol.58, issue.11, pp.2532-2539, 2017.

P. Valent, A. Orazi, D. P. Steensma, B. L. Ebert, D. Haase et al., Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions, Oncotarget, vol.8, issue.43, pp.73483-73500, 2017.

R. V. Tiu, L. P. Gondek, C. L. O'keefe, P. Elson, J. Huh et al., Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies, Blood, vol.117, issue.17, pp.4552-4560, 2011.

Q. Song, M. Peng, Y. Chu, and S. Huang, Techniques for detecting chromosomal aberrations in myelodysplastic syndromes, Oncotarget, vol.8, issue.37, pp.62716-62729, 2017.

L. P. Gondek, R. Tiu, C. L. O'keefe, M. A. Sekeres, K. S. Theil et al., Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML, Blood, vol.111, issue.3, pp.1534-1542, 2008.

T. Cluzeau, C. Moreilhon, N. Mounier, J. Karsenti, L. Gastaud et al., Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine, Blood Cancer Journal, vol.3, issue.11, pp.e155-e155, 2013.

L. C. Bento, R. P. Correia, C. L. Pitangueiras-mangueira, R. De-souza-barroso, F. A. Rocha et al., The Use of Flow Cytometry in Myelodysplastic Syndromes: A Review, Frontiers in Oncology, vol.7, 2017.

M. Maynadié, F. Picard, B. Husson, B. Chatelain, Y. Cornet et al., Immunophenotypic clustering of myelodysplastic syndromes, Blood, vol.100, issue.7, pp.2349-2356, 2002.

K. Ogata, Y. Kishikawa, C. Satoh, H. Tamura, K. Dan et al., Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes, Blood, vol.108, issue.3, pp.1037-1044, 2006.

C. Satoh, K. Dan, T. Yamashita, R. Jo, H. R. Tamura et al., Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes, Leukemia Research, vol.32, issue.5, pp.699-707, 2008.

K. Ogata and Y. Kishikawa, Flow cytometry « Ogata score » for the diagnosis of myelodysplastic syndromes in a real-life setting. A Latin American experience

M. Hong and G. He, The 2016 revision to the World Health Organization classification of myelodysplastic syndromes, Journal of Translational Internal Medicine, vol.5, issue.3, pp.139-143, 2017.

C. Kelaidi, A. Rocha, and P. Fenaux, Syndrome 5q- : caractéristiques hématologiques, physiopathologie et traitement. Hématologie. 29 sept, vol.14, pp.259-69, 2008.

, Insuffisances médullaires et autres cytopénies chroniques, Oncologie, vol.10, issue.11, pp.686-689, 2008.

U. Germing and A. Kündgen, Prognostic scoring systems in MDS, Leukemia Research, vol.36, issue.12, pp.1463-1469, 2012.

P. L. Greenberg, H. Tuechler, J. Schanz, G. Sanz, G. Garcia-manero et al., Revised International Prognostic Scoring System for Myelodysplastic Syndromes, Blood, vol.120, issue.12, pp.2454-2465, 2012.

M. Breccia, A. Salaroli, G. Loglisci, and G. Alimena, Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine, Annals of Hematology, vol.92, issue.3, pp.411-412, 2012.

M. A. Sekeres, A. S. Swern, P. Fenaux, P. L. Greenberg, G. F. Sanz et al., Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q), Blood Cancer Journal, vol.4, issue.8, pp.e242-e242, 2014.

D. Porta, M. G. Alessandrino, E. P. Bacigalupo, A. Van-lint, M. T. Malcovati et al., Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R, Blood. 10 avr, vol.123, issue.15, pp.2333-2375, 2014.

D. P. Steensma, Myelodysplastic syndromes current treatment algorithm 2018, Blood Cancer Journal, vol.8, issue.5, 2018.

M. De-montalembert, J. Ribeil, V. Brousse, A. Guerci-bresler, A. Stamatoullas et al., Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome, PLOS ONE, vol.12, issue.3, p.e0172147, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02377929

M. Breccia, P. Finsinger, G. Loglisci, V. Federico, M. Santopietro et al., Deferasirox treatment for myelodysplastic syndromes: ?real-life? efficacy and safety in a single-institution patient population, Annals of Hematology, vol.91, issue.9, pp.1345-1349, 2012.

S. Park, C. Kelaidi, R. Sapena, D. Vassilieff, O. Beyne-rauzy et al., Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients, Leukemia Research, vol.34, issue.11, pp.1430-1436, 2010.

C. De-transparence-has--eprex.-disponible and . Sur,

C. K. Brierley and D. P. Steensma, Thrombopoiesis-stimulating agents and myelodysplastic syndromes, British Journal of Haematology, vol.169, issue.3, pp.309-323, 2015.

A. M. Zeidan, Y. Linhares, and S. D. Gore, Current therapy of myelodysplastic syndromes, Blood Reviews, vol.27, issue.5, pp.243-259, 2013.

C. De-transparence-has--visaza.-disponible-sur-;-gore, S. D. Fenaux, P. Santini, V. Bennett, J. M. Silverman et al., A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial, Haematologica. juill, vol.98, issue.7, p.1067, 2013.

A. Gil-perez and G. Montalban-bravo, Management of myelodysplastic syndromes after failure of response to hypomethylating agents, Therapeutic Advances in Hematology, vol.10, p.204062071984705, 2019.

F. Baidoun, D. Chen, H. Alkhateeb, D. Zblewski, M. Elliott et al., Clinical Outcome of Patients Diagnosed with Myelodysplastic Syndrome-Unclassifiable (MDS-U): Single Center Experience, Blood, vol.124, issue.21, pp.3264-3264, 2014.

A. Zblewski and D. , Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From, 2004.

C. Strupp, K. Nachtkamp, B. Hildebrandt, A. Giagounidis, R. Haas et al., New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types, Leukemia Research, vol.57, pp.78-84, 2017.

E. Margolskee, R. P. Hasserjian, D. Hassane, W. Tam, S. Mathew et al., Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis, American Journal of Clinical Pathology, vol.148, issue.1, pp.49-57, 2017.

S. Knipp, C. Strupp, N. Gattermann, B. Hildebrandt, M. Schapira et al., Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome, Leukemia Research, vol.32, issue.1, pp.33-37, 2008.

A. Matsuda, U. Germing, I. Jinnai, K. Araseki, A. Kuendgen et al., Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes, Leukemia Research, vol.34, issue.8, pp.974-980, 2010.

R. Pierre, Table 1?source data 1. Human HTML Annokey search results that include hyperlinks to NCBI Gene, GeneRIF and Pubmed databases.

J. P. Maciejewski, A. Risitano, E. M. Sloand, O. Nunez, and N. S. Young, Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia, Blood, vol.99, issue.9, pp.3129-3135, 2002.

D. P. Steensma, G. W. Dewald, J. M. Hodnefield, A. Tefferi, and C. A. Hanson, Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?, Leukemia Research, vol.27, issue.3, pp.235-242, 2003.

S. Jaiswal, P. Fontanillas, J. Flannick, A. Manning, P. V. Grauman et al., Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes, New England Journal of Medicine, vol.371, issue.26, pp.2488-2498, 2014.

D. P. Steensma, R. Bejar, S. Jaiswal, R. C. Lindsley, M. A. Sekeres et al., Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, vol.126, issue.1, pp.9-16, 2015.

R. Bejar, What biologic factors predict for transformation to AML?, Best Practice & Research Clinical Haematology, vol.31, issue.4, pp.341-345, 2018.

J. Mcgowan-jordan, A. Simons, and M. Schmid, ISCN 2016, 2016.

C. Dourmap-collas, Organisation du suivi des dissections aortiques aiguës. Registre IRAD et registre national SFC-SFR-SCTCV, Les Syndromes aortiques aigus, pp.163-167, 2009.

R. S. Tanizawa, C. A. Kumeda, R. S. Azevedo-neto, A. D. Leal, P. D. Ferreira et al., Karyotypic and fluorescent in situ hybridization study of the centromere of chromosome 7 in secondary myeloid neoplasms, Revista Brasileira de Hematologia e Hemoterapia, vol.33, issue.6, pp.425-431, 2011.

D. Sur,

J. Schanz, H. Tüchler, F. Solé, M. Mallo, E. Luño et al., New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge, Journal of Clinical Oncology, vol.30, issue.8, pp.820-829, 2012.

L. Senent, L. Arenillas, E. Luno, J. C. Ruiz, G. Sanz et al., Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes, Haematologica, vol.98, issue.4, pp.568-575, 2012.

G. Recommandations-du and . Disponible, Recommandations du GFHC pour le compte rendu de résultat de l?hémogramme, Option/Bio, vol.27, issue.553-554, pp.17-21, 2016.

P. Font, J. Loscertales, C. Soto, P. Ricard, C. P. Novas et al., Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts, Annals of Hematology, vol.94, issue.4, pp.565-573, 2014.

B. J. Bain, The bone marrow aspirate of healthy subjects, British Journal of Haematology, vol.94, issue.1, pp.206-209, 1996.

M. Cazzola, M. Rossi, and L. Malcovati, Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms, Blood, vol.121, issue.2, pp.260-269, 2013.

A. Matsuda, U. Germing, I. Jinnai, M. Iwanaga, M. Misumi et al., Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification, Leukemia, vol.21, issue.4, pp.678-686, 2007.

N. Kawai, A. Matsuda, I. Jinnai, T. Ichimura, H. Kayano et al., Proposal of criteria for dyserythropoiesis in the diagnosis of myelodysplastic syndromes, International Journal of Hematology, vol.103, issue.2, pp.227-233, 2015.

A. Matsuda, Myelodysplastic Syndromes, Flow Cytometry in Neoplastic Hematology, vol.58, pp.331-340, 2017.

D. Porta, M. G. Travaglino, E. Boveri, E. Ponzoni, M. Malcovati et al., Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes, Leukemia. janv, vol.29, issue.1, pp.66-75, 2015.

K. Petrova-drus, R. Hasserjian, O. Pozdnyakova, P. Dal-cin, S. Mathew et al., Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome, Leukemia & Lymphoma, vol.58, issue.3, pp.569-577, 2016.

O. K. Weinberg and R. P. Hasserjian, The current approach to the diagnosis of myelodysplastic syndromes?, Seminars in Hematology, vol.56, issue.1, pp.15-21, 2019.

A. Wiktor, B. A. Rybicki, Z. S. Piao, M. Shurafa, B. Barthel et al., Clinical significance of Y chromosome loss in hematologic disease, Genes, Chromosomes and Cancer, vol.27, issue.1, pp.11-16, 2000.

C. A. Hanson, D. P. Steensma, J. M. Hodnefield, P. L. Nguyen, J. D. Hoyer et al., Isolated Trisomy 15, American Journal of Clinical Pathology, vol.129, issue.3, pp.478-485, 2008.

E. J. Sinclair, A. M. Potter, A. E. Watmore, M. Fitchett, and F. Ross, Trisomy 15 Associated with Loss of the Y Chromosome in Bone Marrow, Cancer Genetics and Cytogenetics, vol.105, issue.1, pp.20-23, 1998.

. Clinicien-responsable-du-dossier, . Nom, :. Prénom, and . ??????????????????????????????,

:. Centre, . ??????????????????????????????????, :. Adresse, and . ?????????????????????????????????, 5. DIE LETZTE ADRESSE, Anruf, Adresse, Appell
URL : https://hal.archives-ouvertes.fr/hal-02824353

:. Tel, . .. ???????????????????, and . Fax, ????????????? Mail :??????????????????????????????????? IDENTIFICATION DU PATIENT NOM : 3 premières lettres du nom

. Date-de-naissance, L?autobiographie (selon la date de naissance des auteurs), L'autobiographie irlandaise, pp.273-289

(. Sexe and F. Clinico-biologiques, Confrontations clinico-biologiques dans la schizophrénie et les troubles bipolaires, PSN, vol.3, issue.2, pp.109-110, 2005.

, IV. KRONISCHE MYELOIDE LEUKÄMIE, Acta Medica Scandinavica, vol.105, issue.S112, pp.74-105, 2009.